Beam Therapeutics to Participate in RBC Capital Markets 2024 Global Healthcare Conference
08 mai 2024 06h30 HE
|
Beam Therapeutics
CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...
Beam Therapeutics Reports Pipeline Updates and First Quarter 2024 Financial Results
07 mai 2024 06h30 HE
|
Beam Therapeutics
Dosing Completed for Sentinel Cohort of BEACON Phase 1/2 Trial of BEAM-101 in Severe Sickle Cell Disease; Expansion Cohort Initiated Clinical Trial Authorisation (CTA) Application Cleared for the...
Beam Therapeutics Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
26 mars 2024 06h30 HE
|
Beam Therapeutics
Beam Therapeutics Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
Beam Therapeutics to Participate in Upcoming March 2024 Investor Conferences
28 févr. 2024 06h30 HE
|
Beam Therapeutics
CAMBRIDGE, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...
Beam Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Reiterates Anticipated Milestones
27 févr. 2024 06h30 HE
|
Beam Therapeutics
Patient Dosing and Enrollment Continue to Progress in Beacon Phase 1/2 Study of BEAM-101 in Severe Sickle Cell Disease; First Clinical Data Anticipated in Second Half of 2024 Phase 1 Trial Initiation...
Beam Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
05 févr. 2024 06h30 HE
|
Beam Therapeutics
CAMBRIDGE, Mass., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...
Beam Therapeutics Highlights Progress Across Base Editing Portfolio and Outlines 2024 Anticipated Milestones
08 janv. 2024 06h30 HE
|
Beam Therapeutics
Beam Therapeutics Highlights Progress Across Base Editing Portfolio and Outlines 2024 Anticipated Milestones
Beam Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
02 janv. 2024 06h30 HE
|
Beam Therapeutics
CAMBRIDGE, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...
Beam Therapeutics Appoints Biotech Executive Christi Shaw to its Board of Directors
14 déc. 2023 06h30 HE
|
Beam Therapeutics
Beam Therapeutics Appoints Biotech Executive Christi Shaw to its Board of Directors
Beam Therapeutics to Participate in 2023 Jefferies London Healthcare Conference
08 nov. 2023 06h30 HE
|
Beam Therapeutics
CAMBRIDGE, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...